Life Sciences Tools and Services
Company Overview of Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation engages in immune-based discoveries and diagnostics by developing sequencing assays for research and drug development needs. It offers an immunoSEQ hsTCRB kit and analyzer to profile T-cell and B-cell receptor genes. The company provides tools and services for researchers and clinicians (at academic centers and biopharmaceutical companies) to diagnose, treat, and monitor patients with cancers, minimal residual diseases, autoimmune disorders, infectious diseases, and other immune-mediated diseases via its proprietary immune profiling sequencing technology. It serves customers worldwide. Adaptive Biotechnologies Corporation was formerly known as Adaptive TC...
1551 Eastlake Avenue East
Seattle, WA 98102
Founded in 2009
Key Executives for Adaptive Biotechnologies Corporation
Founder, Chief Executive Officer, President and Director
Senior Vice President of Operations
Compensation as of Fiscal Year 2015.
Adaptive Biotechnologies Corporation Key Developments
Adaptive Biotechnologies Corporation Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 09:50 AM
May 17 15
Adaptive Biotechnologies Corporation Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 09:50 AM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Sharon Benzeno, Senior Director, New Product Development.
Adaptive Biotechnologies Corporation Presents at UBS Global Healthcare Conference, May-19-2015 10:30 AM
May 15 15
Adaptive Biotechnologies Corporation Presents at UBS Global Healthcare Conference, May-19-2015 10:30 AM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Julie Rubinstein, Senior Vice President of Business Development.
Adaptive Biotechnologies' immunoSEQ Assay Provides Insight into T-Cell Fate, Significantly Advancing Understanding of Adaptive Immunity
May 11 15
Adaptive Biotechnologies demonstrated in issue of Nature Medicine the ability of the immunoSEQ® Assay to interrogate cell fate in naturally occurring T-cell populations. Contrary to previous thinking, the results show that different types of T cells often descend from a common ancestor. These findings are an advance in the understanding of adaptive immunity and its potential role in pathogenic response. In the study, Adaptive's immunoSEQ Assay was used to comprehensively characterize the antigen-reactive T-cell repertoires in non-transgenic mice exposed to multiple antigens to interrogate cell fate in naturally occurring T-cell immune responses.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 5, 2015
January 7, 2015
January 7, 2015